Table 3.
Comparisons of genotype and allele distributions of IL-1β, MMP-3, TGF-β1, and GDF5 polymorphisms between patients with PFS and controls.
| SNP | Cases | Controls | OR (95% CI) | P value |
|---|---|---|---|---|
| n (%) | n (%) | |||
|
IL-1β rs1143627 |
||||
| Genotype | ||||
| TT | 14 (33.3) | 15 (30.0) | 1.00a | |
| TC | 26 (61.9) | 22 (44.0) | 1.27 (0.50–3.19) | 0.616 |
| CC | 2 (4.8) | 13 (26.0) | 0.17 (0.03–0.87) | 0.022 |
| TC + CC | 28 (66.7) | 35 (35.0) | 0.86 (0.36–2.07) | 0.732 |
| Allele | ||||
| T | 54 (64.3) | 52 (52.0) | 1.00a | |
| C | 30 (35.7) | 48 (48.0) | 0.60 (0.33–1.09) | 0.093 |
|
MMP-3 rs650108 |
||||
| Genotype | ||||
| AA | 18 (42.9) | 20 (40.0) | 1.00a | |
| AG | 16 (48.1) | 21 (42.0) | 0.85 (0.34–2.10) | 0.720 |
| GG | 8 (19.0) | 9 (18.0) | 0.99 (0.34–3.11) | 0.983 |
| AG + GG | 24 (67.1) | 30 (60.0) | 0.89 (0.39–2.04) | 0.782 |
| Allele | ||||
| A | 52 (61.9) | 61 (61.0) | 1.00a | |
| G | 32 (38.1) | 39 (39.0) | 0.96 (0.53–1.75) | 0.900 |
|
TGF-β1 rs1800469 |
||||
| Genotype | ||||
| CC | 9 (21.4) | 13 (26.0) | 1.00a | |
| CT | 23 (54.8) | 24 (48.0) | 1.38 (0.50–0.39) | 0.533 |
| TT | 10 (23.8) | 13 (26.0) | 1.11 (0.34–3.63) | 0.862 |
| CT + TT | 33 (78.6) | 37 (74.0) | 1.29 (0.49–3.40) | 0.609 |
| Allele | ||||
| C | 41 (48.9) | 50 (50.0) | 1.00a | |
| T | 43 (51.1) | 50 (50.0) | 1.05 (0.59–1.87) | 0.872 |
|
GDF5 rs143383 |
||||
| Genotype | ||||
| TT | 22 (52.4) | 24 (48.0) | 1.00a | |
| TC | 18 (42.9) | 22 (44.0) | 0.89 (0.38–2.09) | 0.793 |
| CC | 2 (4.8) | 4 (8.0) | 1.54 (0.42–5.64) | 0.513 |
| TC + CC | 20 (47.7) | 26 (52.0) | 0.84 (0.37–1.91) | 0.675 |
| Allele | ||||
| T | 62 (73.8) | 70 (70.0) | 1.00a | |
| C | 22 (26.2) | 30 (30.0) | 1.07 (0.58–1.98) | 0.828 |
aReference genotype/allele; CI: confidence interval; OR: odds ratio; PFS: primary frozen shoulder; SNP: single nucleotide polymorphism.